Home
News
Create
Screeners
Insights
Samrat Pharmachem
206.
45
+8.55
(+4.32%)
Market Cap
₹63.84 Cr
PE Ratio
-36.51
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+4.32%
1M
-1.41%
6M
-34.97%
1Y
-36.69%
5Y
+48.63%
View Company Insights
Latest news about Samrat Pharmachem
Samrat Pharmachem Limited Receives Credit Rating Upgrade from Crisil
5 days ago
Samrat Pharmachem Limited has received a credit rating upgrade from Crisil Limited, with the rating on bank facilities revised to 'Crisil BB/Stable/Crisil A4+' from 'Crisil BB+/Negative/Crisil A4+'. The pharmaceutical chemicals manufacturer disclosed this development in compliance with SEBI regulations, with the information made available on the company's official website for stakeholder reference.
Samrat Pharmachem Limited Schedules Board Meeting on May 30, 2026 for FY26 Audited Financial Results
10 days ago
Samrat Pharmachem Reports Q3 FY26 Loss of Rs 45.95 Lakhs Against Prior Year Profit
Feb 18, 2026
Samrat Pharmachem Reports Q2 FY26 Loss Despite Revenue Growth
Nov 15, 2025
Samrat Pharmachem Reappoints Key Executives, Maintaining Family Leadership
Jul 25, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO